Ms. Samira Sakhia reports

KNIGHT ANNOUNCES EARLY WARNING FILING REGARDING SHARES OF CRESCITA

This press release has been disseminated by Knight Therapeutics Inc. as required by Regulation 62-103 respecting the early warning system and related takeover bid and insider reporting issues regarding securities of Crescita Therapeutics Inc.

Crescita has announced the closing of the previously announced plan of arrangement with ClinActiv Holdings Inc. and its wholly owned subsidiary (the purchaser), pursuant to which the purchaser acquired all the issued and outstanding common shares of Crescita in exchange for a cash consideration of 80 cents per share.

Prior to the closing of the arrangement, Knight had control over 1,935,489 shares, representing approximately 10.4 per cent of the issued and outstanding shares of Crescita. After closing of the arrangement, Knight no longer holds any shares, has ceased to be an insider of Crescita and is no longer subject to the early warning reporting requirements under Regulation 62-103.

For further information or to obtain a copy of the early warning report to which this press release relates, please contact Samira Sakhia at 514-484-4483.

About Knight Therapeutics Inc.

Knight Therapeutics, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics' shares trade on the Toronto Stock Exchange under the symbol GUD.

We seek Safe Harbor.